Despite significant efforts to prevent stroke in patients, there remains an unmet need among providers regarding the optimization and benefit-risk profile of anticoagulation therapies. This satellite symposium will focus on secondary stroke prevention and the prevention of ischemic stroke in patients with atrial fibrillation.
Factoring Solutions to the Management of Stroke Care in the Settings of Secondary Prevention and AF
Join the experts in this satellite symposium focused on secondary stroke prevention and the prevention of ischemic stroke in patients with AF.
Live
Meeting
1.50 available credits
Information
February 6, 2025
05:30 PM - 07:30 PM PT
JW Marriott Los Angeles L.A. LIVE
900 W Olympic Blvd, Los Angeles, CA 90015, Room: Gold 3-4 (Ground Level), Los Angeles, California, United States
Share
Share
Share
Share this program on:
Details
Presenters
Comments
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Host:
M. Edip Gurol, MD, MSc
Vascular Neurologist, Associate Professor of Neurology
Director, High Hemorrhage Risk Stroke Prevention Clinic
Director, Neuro-AFib Program
Massachusetts General Hospital
Harvard Medical School
Boston, MA
No relevant financial relationships have been reported at this time.
Faculty:
Jeffrey Weitz, MD
Professor of Medicine & Biochemistry
McMaster University
Hamilton, ON, Canada
Dr. Weitz has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Alnylam, Anthos, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Ionis, Janssen, Merck, Novartis, Pfizer, Regeneron, Servier
Additional faculty will be announced soon!
Reviewers/Content Planners/Authors:- Cindy Davidson has no relevant financial relationships with ineligible companies.
- Brian P. McDonough, MD, FAAFP, has no relevant financial relationships with ineligible companies.
- Kathleen Sheridan, PhD, has no relevant financial relationships with ineligible companies.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Identify the clinical indications for antiplatelet and anticoagulation therapies in patients at risk of ischemic stroke, including the differentiation between patient profiles that benefit from each treatment approach
- Discuss factor XI inhibition and review new and emerging anticoagulation pharmacotherapy for secondary stroke prevention
- Comprehend the clinical indications for various anticoagulation therapies in the management of acute ischemic stroke, including the criteria for and limitations of current therapies
- Discuss factor XI inhibition and review new and emerging anticoagulation pharmacotherapy for ischemic stroke prevention
Target Audience
This activity has been designed to meet the educational needs of neurologists and cardiologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in the primary and secondary prevention of ischemic stroke.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.5 contact hours/0.15 CEUs of pharmacy contact hours.
The Universal Activity Number for this program is JA0006235-0000-25-004-L01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credit(s). PAs should claim only the credit commensurate with the extent of their participation in the activity.Provider(s)/Educational Partner(s)
It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.Commercial Support
This activity is supported by independent educational grants from Bristol Myers Squibb and Johnson & Johnson Innovative Medicine Alliance.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Total CME, LLC, you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.ADA Statement
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Andrea Mathis prior to the live event at amathis@glc.healthcare.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Details
Presenters
Comments
Overview
Despite significant efforts to prevent stroke in patients, there remains an unmet need among providers regarding the optimization and benefit-risk profile of anticoagulation therapies. This satellite symposium will focus on secondary stroke prevention and the prevention of ischemic stroke in patients with atrial fibrillation.
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Host:
M. Edip Gurol, MD, MSc
Vascular Neurologist, Associate Professor of Neurology
Director, High Hemorrhage Risk Stroke Prevention Clinic
Director, Neuro-AFib Program
Massachusetts General Hospital
Harvard Medical School
Boston, MA
No relevant financial relationships have been reported at this time.
Faculty:
Jeffrey Weitz, MD
Professor of Medicine & Biochemistry
McMaster University
Hamilton, ON, Canada
Dr. Weitz has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Alnylam, Anthos, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Ionis, Janssen, Merck, Novartis, Pfizer, Regeneron, Servier
Additional faculty will be announced soon!
Reviewers/Content Planners/Authors:- Cindy Davidson has no relevant financial relationships with ineligible companies.
- Brian P. McDonough, MD, FAAFP, has no relevant financial relationships with ineligible companies.
- Kathleen Sheridan, PhD, has no relevant financial relationships with ineligible companies.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Identify the clinical indications for antiplatelet and anticoagulation therapies in patients at risk of ischemic stroke, including the differentiation between patient profiles that benefit from each treatment approach
- Discuss factor XI inhibition and review new and emerging anticoagulation pharmacotherapy for secondary stroke prevention
- Comprehend the clinical indications for various anticoagulation therapies in the management of acute ischemic stroke, including the criteria for and limitations of current therapies
- Discuss factor XI inhibition and review new and emerging anticoagulation pharmacotherapy for ischemic stroke prevention
Target Audience
This activity has been designed to meet the educational needs of neurologists and cardiologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in the primary and secondary prevention of ischemic stroke.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.Global Learning Collaborative (GLC) designates this activity for 1.5 contact hours/0.15 CEUs of pharmacy contact hours.
The Universal Activity Number for this program is JA0006235-0000-25-004-L01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credit(s). PAs should claim only the credit commensurate with the extent of their participation in the activity.Provider(s)/Educational Partner(s)
It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.Commercial Support
This activity is supported by independent educational grants from Bristol Myers Squibb and Johnson & Johnson Innovative Medicine Alliance.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Total CME, LLC, you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.ADA Statement
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Andrea Mathis prior to the live event at amathis@glc.healthcare.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Recommended
Pulmonary Hypertension Management: Practice Trends and Updates
Pulmonary Hypertension Management: Practice Trends and Updates
CME/CE Broadcast ReplayPulmonary Hypertension Management: Practice Trends and Updates
1.00 credit
Vallerie V. McLaughlin, MD
Victor Moles, MD
Ioana Preston, MD
1.00 creditPulmonary Hypertension: Comorbidities With PAH and Group 2 PH
Pulmonary Hypertension: Comorbidities With PAH and Group 2 PH
CME/CE Broadcast ReplayPulmonary Hypertension: Comorbidities With PAH and Group 2 PH
1.00 creditVallerie V. McLaughlin, MD
Thomas Cascino, MD
Bradley A. Maron, MD
1.00 credit- NEW EPISODE
The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
MinuteCE®The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
0.75 program creditsHarry Yoon, MD
0.75 program credits - NEW EPISODE
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
MinuteCE®Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
0.75 program creditsJaffer Ajani, MD
0.75 program credits